Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to evaluate the risk factors of PNAC in neonates


Clinical Trial Description

Neonates with prematurity,gastrointestinal dysfunction and very low birth weights are often intolerant to oral feeding.In such infants,the provision of nutrients via parenteral nutrition (PN)becomes necessary for short term survival,as well as long-term health. Wilmore and Dudrick first reported use of parenteral nutrition(PN) for an infant more than 40years ago Soon there after physicians recognized that PN was associated with significant liver changes.In the first reported case of parenteral nutrition-associated conjugated hyperbilirubinemia (PNAC) in a premature infant hepatomegaly was noted on the18thday of fat-free PN and worsened until death on the71st day of life The hyperbilirubinemia manifest in PNAC is thought to occur from impaired hepatic bileflow, an adynamic gallbladder,and an upsurge in release of conjugated bilirubin as an infant matures.Atbirth,preterm neonates havereduced activity of the uridine diphosphate glucuronosyl transferase1A1 liver enzyme(UDPGT)that catalyzes conjugation of bilirubin As the infant develops,UDPGT becomes more functional, increasing hepatocyte efficiency for conjugation.Thus,in combination with cholestasis,and neonatal intestinal absorption of unconjugated bilirubin,more conjugated bilirubin is made available to pass from the liver into circulation. Parenteral nutrition associated cholestasis (PNAC) is the most common form of liver damage in neonates while receiving parenteral nutrition(PN).Its prevalence was reported between10%and 60%in NICU Cholestasisis acommonly described complication of PN. Its etiology is not fully understood and is thought to be multifactorial Proposed mechanisms included altered bile salt metabolisms secondary to prematurity and toxic effect of PN components on the liver the presence or absence of specific components in parenteral nutrition solutions most certainly contributing to the disease mechanism,and gastrointestinal systems .Aggravating factors such as sepsis and duration of bowel rest have also been described ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05163145
Study type Observational
Source Assiut University
Contact Mayyada ElsayedMohamed, resident
Phone 01002686656
Email soadalsayed2@gmail.com
Status Not yet recruiting
Phase
Start date July 1, 2022
Completion date March 2, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06048211 - Impact of the Stool Color Scale on the Detection of Neonatal Cholestasis
Recruiting NCT03842150 - Development and Validation of a Screening Score for the Biliary Atresia in Infantile Cholestasis: A Prospective Study
Completed NCT01875510 - The Influence of Fish-oil Lipid Emulsions on Neonatal Morbidities N/A
Recruiting NCT00061828 - A Prospective Database of Infants With Cholestasis
Not yet recruiting NCT03898765 - Dry Blood Spot Screening Test for Biliary Atresia(DBS-SCReBA) N/A